keyword
MENU ▼
Read by QxMD icon Read
search

Taxan

keyword
https://www.readbyqxmd.com/read/29236294/acute-myeloid-leukemia-and-myelodysplastic-syndrome-after-adjuvant-chemotherapy-a-population-based-study-among-older-breast-cancer-patients
#1
Aron S Rosenstock, Jiangong Niu, Sharon H Giordano, Hui Zhao, Antonio C Wolff, Mariana Chavez-MacGregor
BACKGROUND: Chemotherapy for early breast cancer is associated with a small risk of developing myelodysplastic syndrome (MDS) and/or acute myeloid leukemia (AML). The aim of this study was to determine the risk of developing AML or MDS after modern adjuvant chemotherapy in older breast cancer patients and to further define the risk of individual chemotherapy regimens. METHODS: Patients diagnosed with stage I to III breast cancer from 2003 to 2009 were identified in the Surveillance, Epidemiology, and End Results-Medicare and Texas Cancer Registry-Medicare linked databases...
December 13, 2017: Cancer
https://www.readbyqxmd.com/read/29228548/macrophage-depletion-through-colony-stimulating-factor-1-receptor-pathway-blockade-overcomes-adaptive-resistance-to-anti-vegf-therapy
#2
Yasmin A Lyons, Sunila Pradeep, Sherry Y Wu, Monika Haemmerle, Jean M Hansen, Michael J Wagner, Alejandro Villar-Prados, Archana S Nagaraja, Robert L Dood, Rebecca A Previs, Wei Hu, Yang Zhao, Duncan H Mak, Zhilan Xiao, Brenda D Melendez, Gregory A Lizee, Imelda Mercado-Uribe, Keith A Baggerly, Patrick Hwu, Jinsong Liu, Willem W Overwijk, Robert L Coleman, Anil K Sood
Anti-angiogenesis therapy has shown clinical benefit in patients with high-grade serous ovarian cancer (HGSC), but adaptive resistance rapidly emerges. Thus, approaches to overcome such resistance are needed. We developed the setting of adaptive resistance to anti-VEGF therapy, and performed a series of in vivo experiments in both immune competent and nude mouse models. Given the pro-angiogenic properties of tumor-associated macrophages (TAMs) and the dominant role of CSF1R in macrophage function, we added CSF1R inhibitors following emergence of adaptive resistance to anti-VEGF antibody...
November 14, 2017: Oncotarget
https://www.readbyqxmd.com/read/29228315/comparison-of-neoadjuvant-nab-paclitaxel-carboplatin-vs-nab-paclitaxel-gemcitabine-in-triple-negative-breast-cancer-randomized-wsg-adapt-tn-trial-results
#3
Oleg Gluz, Ulrike Nitz, Cornelia Liedtke, Matthias Christgen, Eva-Maria Grischke, Helmut Forstbauer, Michael Braun, Mathias Warm, John Hackmann, Christoph Uleer, Bahriye Aktas, Claudia Schumacher, Nikola Bangemann, Christoph Lindner, Sherko Kuemmel, Michael Clemens, Jochem Potenberg, Peter Staib, Andreas Kohls, Raquel von Schumann, Ronald Kates, Ronald Kates, Johannes Schumacher, Rachel Wuerstlein, Hans Heinrich Kreipe, Nadia Harbeck
Background: Pathological complete response (pCR) is associated with improved prognosis in triple-negative breast cancer (TNBC). The optimal chemotherapy regimen is unclear. Weekly nab-paclitaxel vs conventional paclitaxel or addition of carboplatin to anthracycline-taxane results in higher pCR rates with uncertain survival impact. We evaluated carboplatin vs gemcitabine with a nab-paclitaxel backbone as a short 12-week A-free regimen with a focus on early response. Methods: Patients with TNBC (estrogen receptor/progesterone receptor < 1%, human epidermal growth factor receptor 2-negative, cT1c-cT4c, cN0/+) were randomly assigned to A: nab-paclitaxel 125 mg/m2/gemcitabine 1000 mg/m2 d1,8 three times weekly (q3w); vs B: nab-paclitaxel 125 mg/m2/carboplatin AUC2 day 1,8 q3w...
December 8, 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/29224823/results-of-a-phase-ii-randomized-controlled-clinical-trial-comparing-efficacy-of-cabazitaxel-versus-docetaxel-as-second-line-or-above-therapy-in-recurrent-head-and-neck-cancer
#4
Amit Joshi, Vijay Patil, Vanita Noronha, Sachin Dhumal, Nikhil Pande, Arun Chandrasekharan, Siddharth Turkar, Hollis DSouza, Sameer Shrirangwar, Abhishek Mahajan, Supreeta Arya, Shashikant Juvekar, Atanu BhattaCharjee, Kumar Prabhash
BACKGROUND: Cabazitaxel has shown activity in squamous cancer cell lines and in taxane resistant cell lines. Hence we planned a phase 2 study to evaluate the efficacy of cabazitaxel against Docetaxel in recurrent head and neck cancer, post first line treatment. METHODS: This was a phase 2, investigator initiated, randomized controlled trial of Docetaxel (75 mg/m2) versus Cabazitaxel (20 mg/m2), in patients with head and neck cancer with ECOG performance status 0-2 who have been exposed to at least one line of chemotherapy, involving a sample size of 92 (46 per group)(CTRI/2015/06/005848)...
December 2017: Oral Oncology
https://www.readbyqxmd.com/read/29222650/taxane-platinum-and-5-fu-prior-to-chemoradiotherapy-benefits-patients-with-stage-iv-neck-node-positive-head-and-neck-cancer-and-a-good-performance-status
#5
Natalie M Lowe, Jonathan M Bernstein, Kathleen Mais, Kate Garcez, Lip W Lee, Andrew Sykes, David J Thomson, Jarrod J Homer, Catharine M West, Nicholas J Slevin
PURPOSE: The benefit of adding docetaxel, cisplatin and 5-fluorouracil (TPF) induction chemotherapy to chemoradiotherapy (CRT) in head and neck squamous cell carcinoma (HNSCC) remains uncertain. We aimed to investigate whether ICT is well tolerated when given with prophylactic treatment against predicted adverse effects and which patients benefit most. METHODS: A single-centre audit identified 132 HNSCC patients with stage IVa/b neck node-positive disease, prescribed TPF followed by CRT...
December 8, 2017: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/29221164/inhibition-of-x-linked-inhibitor-of-apoptosis-protein-suppresses-tumorigenesis-and-enhances-chemosensitivity-in-anaplastic-thyroid-carcinoma
#6
Yao Liu, Bing Zhang, Tiefeng Shi, Huadong Qin
Anaplastic thyroid carcinoma (ATC) is one of the most lethal carcinoma with a poor prognosis; however, molecular mechanisms underlying the aggressiveness of ATC remain unclear. Our goal was to examine the expression of X-linked inhibitor of apoptosis protein (XIAP) in ATC, as well as its role in ATC tumorigenesis. This is a retrospective study of ATC patients from the Second Affiliated Hospital of Harbin Medical University during June 2003 to October 2013. The expression of XIAP in tumor specimens of ATC patients was examined by immunohistochemical staining...
November 10, 2017: Oncotarget
https://www.readbyqxmd.com/read/29219049/role-of-mitochondrial-mechanism-in-chemotherapy-induced-peripheral-neuropathy
#7
Mohammad Waseem, Pooja Kaushik, Heena Tabassum, Suhel Parvez
BACKGROUND: Even though chemotherapeutic regimens shows considerable importance, it may cause progressive, continuing and sometimes irreversible peripheral neuropathy. Chemotherapy induced peripheral neuropathy (CIPN) comprises of sensory abnormalities that are most distress issues. The mechanism associated with CIPN pathogenesis is not completely revealed and is treatment is still questionable. The purpose of this review was to investigate the role of mitochondria in CIPN. METHODS: This review is literature based that describes the mitochondrial mechanism underlying CIPN and the neuropathic complications associated with different antineoplastic agents...
December 7, 2017: Current Drug Metabolism
https://www.readbyqxmd.com/read/29212614/clinical-trials-in-gynecologic-oncology-past-present-and-future
#8
REVIEW
Christina M Annunziata, Elise C Kohn
The Gynecologic Oncology Group has historically performed ground-breaking, practice-changing clinical trials in women's cancers. The current standard of care for initial treatment of ovarian, endometrial, cervical, and trophoblastic cancers was determined by clinical trials completed within this cooperative group structure. For example, trial GOG-0111 set the standard for combining platinum and taxane chemotherapy in ovarian cancer, and more recently GOG-0240 provided evidence for adding bevacizumab to chemotherapy for women with advanced cervical cancer...
December 3, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/29212525/establishing-and-characterizing-patient-derived-xenografts-using-pre-chemotherapy-percutaneous-biopsy-and-post-chemotherapy-surgical-samples-from-a-prospective-neoadjuvant-breast-cancer-study
#9
Jia Yu, Bo Qin, Ann M Moyer, Jason P Sinnwell, Kevin J Thompson, John A Copland, Laura A Marlow, James L Miller, Ping Yin, Bowen Gao, Katherine Minter-Dykhouse, Xiaojia Tang, Sarah A McLaughlin, Alvaro Moreno-Aspitia, Anthony Schweitzer, Yan Lu, Jason Hubbard, Donald W Northfelt, Richard J Gray, Katie Hunt, Amy L Conners, Vera J Suman, Krishna R Kalari, James N Ingle, Zhenkun Lou, Daniel W Visscher, Richard Weinshilboum, Judy C Boughey, Matthew P Goetz, Liewei Wang
BACKGROUND: Patient-derived xenografts (PDXs) are increasingly used in cancer research as a tool to inform cancer biology and drug response. Most available breast cancer PDXs have been generated in the metastatic setting. However, in the setting of operable breast cancer, PDX models both sensitive and resistant to chemotherapy are needed for drug development and prospective data are lacking regarding the clinical and molecular characteristics associated with PDX take rate in this setting...
December 6, 2017: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/29210293/phosphatidylcholine-attenuated-docetaxel-induced-peripheral-neurotoxicity-in-rats
#10
Sung Tae Kim, Eun Jung Kyung, Jung Sook Suh, Ho Sung Lee, Jun Ho Lee, Soo In Chae, Eon Sub Park, Yoon Hee Chung, Jinhyung Bae, Tae Jin Lee, Won Mo Lee, Uy Dong Sohn, Ji Hoon Jeong
Docetaxel is a taxane chemotherapeutic agent used in the treatment of breast cancer, prostate cancer and gastric cancer, but several side effects such as peripheral neurotoxicity could occur. The present study was designed to investigate the therapeutic potential of phosphatidylcholine (PC) on docetaxel-induced peripheral neurotoxicity. Rats were randomly divided into three groups and treated for 4 weeks. Behavioral tests were conducted to measure the effects of PC on docetaxel-induced decreases in mechanical & thermal nociceptive threshold...
December 6, 2017: Drug and Chemical Toxicology
https://www.readbyqxmd.com/read/29209772/influence-of-the-abcb1-polymorphisms-on-the-response-to-taxane-containing-chemotherapy-a-systematic-review-and-meta-analysis
#11
Qi Jiang, Meizhen Xu, Yina Liu, Yudi Chen, Jiarong Feng, Xuelin Wang, Shuang Liang, Dan Li, Xiaoqin Yang
PURPOSE: Multidrug resistance mediated by ABCB1 has been perceived to be one of the obstacles for cancer chemotherapy. This meta-analysis was performed to verify the effect of the ABCB1 rs1045642 and rs1128503 polymorphisms on the response to Taxane-containing chemotherapy. METHODS: Pooled odds ratios (ORs) and corresponding 95% confidence intervals (CIs) were employed to evaluate the impact of these two ABCB1 polymorphisms. R scripts were developed to perform the meta-analysis...
December 5, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/29209523/second-line-treatments-moving-towards-an-opportunity-to-improve-survival-in-advanced-gastric-cancer
#12
REVIEW
Massimiliano Salati, Katia Di Emidio, Vittoria Tarantino, Stefano Cascinu
Gastric cancer is the third leading cause of cancer-related death globally with approximately 723 000 deaths every year. Most patients present with advanced unresectable or metastatic disease, only amenable to palliative systemic treatment and a median survival uncommonly exceeding 12 months. Over the last years, the efficacy of chemotherapy combination has plateaued and the introduction of the anti-human epidermal growth factor receptor 2 trastuzumab has resulted in a limited survival gain in the upfront setting...
2017: ESMO Open
https://www.readbyqxmd.com/read/29205077/forty-years-of-landmark-trials-undertaken-by-the-danish-breast-cancer-cooperative-group-dbcg-nationwide-or-in-international-collaboration
#13
Bent Ejlertsen, Birgitte Vrou Offersen, Jens Overgaard, Peer Christiansen, Maj-Britt Jensen, Niels Kroman, Ann Søgaard Knoop, Henning Mouridsen
BACKGROUND: Over the past 40 years the Danish Breast Cancer Cooperative Group (DBCG) has made significant contributions to improve outcome and to make treatment of patients with early breast cancer more tolerable through nationwide and international trials evaluating loco-regional and systemic treatments. These trials have been instrumental to establish standards for the treatment of early breast cancer. METHODS: The DBCG 82 trials had a global impact by documenting that the significant gain in loco-regional recurrence from postmastectomy radiation added to systemic therapy was associated with a reduction in distant recurrence and mortality in high-risk pre- and postmenopausal patients...
December 5, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/29204847/adjuvant-chemotherapeutic-treatment-of-1650-patients-with-early-breast-cancer-in-routine-care-in-germany-data-from-the-prospective-tmk-cohort-study
#14
Steffen Dörfel, Claus-Christoph Steffens, Dirk Meyer, Hans Tesch, Lisa Kruggel, Melanie Frank, Martina Jänicke, Norbert Marschner
BACKGROUND: Several regimens for which efficacy was established in randomized controlled trials are recommended in current treatment guidelines for early breast cancer. However, knowledge on use and effectiveness of commonly administered chemotherapeutic agents in real-life care and across all breast cancer subtypes is limited. METHODS: The prospective, multicentre German TMK cohort study (Tumour Registry Breast Cancer) recruited patients in 148 oncology outpatient-centres...
December 4, 2017: Breast Cancer: the Journal of the Japanese Breast Cancer Society
https://www.readbyqxmd.com/read/29204710/chemotherapy-related-neuropathic-symptom-management-a-randomized-trial-of-an-automated-symptom-monitoring-system-paired-with-nurse-practitioner-follow-up
#15
Noah Allan Kolb, Albert Gordon Smith, John Robinson Singleton, Susan L Beck, Diantha Howard, Kim Dittus, Summer Karafiath, Kathi Mooney
PURPOSE: The purpose of this study was to evaluate a new care model to reduce chemotherapy-induced neuropathic symptoms. Neuropathic symptom usual care was prospectively compared to an automated symptom-monitoring and coaching system, SymptomCare@Home (SCH), which included nurse practitioner follow-up triggered by moderate to severe symptoms. METHODS: Patients beginning chemotherapy were randomized to usual care (UC) or to the SCH intervention. This sub-analysis included only taxane/platin therapies...
December 5, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/29198326/the-molecular-genetics-of-chemotherapy-induced-peripheral-neuropathy-a-systematic-review-and-meta-analysis
#16
REVIEW
J Cliff, A L Jorgensen, R Lord, F Azam, L Cossar, D F Carr, M Pirmohamed
Chemotherapy-induced peripheral neuropathy (CIPN) can adversely affect completion of systemic anti-cancer treatment and cause long-term morbidity. Increasingly pharmacogenetic studies have been performed to explore susceptibility to this important adverse effect. A systematic review was conducted to identify pharmacogenetic studies, assess their quality and findings and undertake meta-analysis where possible. 93 studies were included. Notable methodological issues included lack of standardisation and detail in phenotype definition and acknowledgement of potential confounding factors...
December 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/29195916/novel-sulforaphane-enabled-self-microemulsifying-delivery-systems-sfn-smedds-of-taxanes-formulation-development-and-in-vitro-cytotoxicity-against-breast-cancer-cells
#17
Mohammad M Kamal, Sami Nazzal
Paclitaxel (PTX) and docetaxel (DTX) are highly effective chemotherapeutic agents against breast cancer cells. Existing PTX and DTX formulations, however, contain excipients that result in a multitude of side-effects. The objective of the present study was to develop novel self-microemulsifying formulations of PTX and DTX with significantly lower excipient content by utilizing the high solubility of taxanes in sulforaphane (SFN). SFN-enabled microemulsions were developed by a screening process in which optical microscopy and absorbance data were used to monitor the physical stability of the dispersions...
November 28, 2017: International Journal of Pharmaceutics
https://www.readbyqxmd.com/read/29190391/radiotherapy-for-locally-advanced-resectable-t3-t4-laryngeal-cancer-does-laryngeal-preservation-strategy-compromise-survival
#18
Hideya Yamazaki, Gen Suzuki, Satoaki Nakamura, Shigeru Hirano, Ken Yoshida, Koji Konishi, Teruki Teshima, Kazuhiko Ogawa
With the advancement of chemotherapy, a laryngeal preservation (LP) strategy was explored with the aim of improving maintenance of quality of life. Induction chemotherapy (ICT) following radiotherapy (RT) was considered a viable option because of its high initial response rate without hampering of overall survival (OS). Subsequently, concurrent chemoradiotherapy (CCRT) using CDDP became the standard of care for LP, showing the best LP ratio. For enhancing treatment intensity, ICT with taxan + CDDP + 5-FU (TPF-ICT) followed by RT showed superiority over ICT with CDDP + 5-FU (PF-ICT) followed by RT...
November 28, 2017: Journal of Radiation Research
https://www.readbyqxmd.com/read/29189915/targeting-brca1-2-deficient-ovarian-cancer-with-cndac-based-drug-combinations
#19
Xiaojun Liu, Yingjun Jiang, Billie Nowak, Bethany Qiang, Nancy Cheng, Yuling Chen, William Plunkett
PURPOSE: The mechanism of action of CNDAC (2'-C-cyano-2'-deoxy-1-β-D-arabino-pentofuranosyl-cytosine) is unique among deoxycytidine analogs because upon incorporation into DNA it causes a single strand break which is converted to a double strand break after DNA replication. This lesion requires homologous recombination (HR) for repair. CNDAC, as the parent nucleoside, DFP10917, and as an oral prodrug, sapacitabine, are undergoing clinical trials for hematological malignancies and solid tumors...
November 30, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/29185274/survival-benefit-of-patients-with-early-stage-ovarian-carcinoma-treated-with-paclitaxel-chemotherapeutic-regimens
#20
Chien An Chen, Chun Ju Chiang, Yun Yuan Chen, San Lin You, Shu Feng Hsieh, Chao Hsiun Tang, Wen Fang Cheng
OBJECTIVE: Adjuvant chemotherapy was introduced in patients with early-stage ovarian cancer (OC). The benefit of standard chemotherapeutic regimens including taxane has not been established. METHODS: Patients with early-stage OC from the National Health Insurance Research database of Taiwan who received platinum plus cyclophosphamide (CP) or platinum plus paclitaxel (PT) for 3-6 cycles were recruited, and the disease-free survival (DFS) and overall survival (OS) were determined...
January 2018: Journal of Gynecologic Oncology
keyword
keyword
64691
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"